[HTML][HTML] The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
RA Van Etten, S Koschmieder, F Delhommeau… - …, 2011 - ncbi.nlm.nih.gov
This review focuses on topical issues in the biology and treatment of the myeloproliferative
neoplasms (MPNs). Studies in transgenic mice suggest that BCR-ABL1 reduces the fraction …
neoplasms (MPNs). Studies in transgenic mice suggest that BCR-ABL1 reduces the fraction …
Where are we going with CML research?
D Perrotti - Leukemia supplements, 2012 - nature.com
The introduction of Abl tyrosine kinase inhibitors (TKI; that is, imatinib, dasatinib and
nilotinib) as front-line therapy completely changed the course of chronic myelogenous …
nilotinib) as front-line therapy completely changed the course of chronic myelogenous …